N-(piperidin-1-yl)-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxamide
AM AM · AM 251 · CS-985 · AM 251 NEW · AM-251 ,99% · AM251 · AM-251 · WIZ degrader 9
Identifikatoren & physikalische Daten
| CAS No. | 183232-66-8 |
|---|---|
| Summenformel | C22H21Cl2IN4O |
| Durchschnittliche Molmasse | 555,2 g/mol |
| Monoisotopische Masse | 554,01371465 g/mol |
| SMILES | Cc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(I)cc1 |
| InChIKey | BUZAJRPLUGXRAB-UHFFFAOYSA-N |
| PubChem CID | 2125 |
| ChEMBL | CHEMBL285932 |
| ChEBI | CHEBI:90724 |
| EC No. | 634-045-8 |
| DTXSID | DTXSID7042695 |
Chemische & physikalische Eigenschaften
| XLogP | 6,5 |
|---|---|
| Polarare Oberfläche (TPSA) | 50,2 |
| H-Brücken-Donoren | 1 |
| H-Brücken-Akzeptoren | 3 |
| Frei drehbare Bindungen | 4 |
| Schwere Atome | 30 |
| Formalladung | 0 |
| Komplexität | 585 |
| LogP (Verteilungskoeffizient) | 4.9 |
| Schmelzpunkt | 195-196℃ |
| Dichte | 1.65±0.1 g/cm3(Predicted) |
| Lagerbedingungen | Store at RT |
| Löslichkeit | DMSO: >10 mg/mL, soluble |
| Aggregatzustand | solid |
| pKa (Säurekonstante) | 11.31±0.20(Predicted) |
| Farbe | white |
| Stabilität | Stable for 1 year as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months. |
| InChI | 1S/C22H21Cl2IN4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-7-16(23)13-18(19)24)21(14)15-5-8-17(25)9-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30) |
| InChIKey | BUZAJRPLUGXRAB-UHFFFAOYSA-N |
| SMILES | Cc1c(nn(-c2ccc(Cl)cc2Cl)c1-c3ccc(I)cc3)C(=O)NN4CCCCC4 |
| CAS Datenbank | 183232-66-8 |
Sicherheit & Vorschriften
| GHS-Einstufung | WarningH315 (97.5%): Causes skin irritation [Warning Skin corrosion/irritation]P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 40 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| Hazard Classes and Categories | Skin Irrit. 2 (97.5%) |
| Wassergefährdungsklasse (WGK) | 3 |
| Zollcode | 2933.39.6190 |
| R-Sätze (R) | 36/37/38 |
| Gefahrensymbole | Xi |
| Sicherheitshinweise (S) | 26-36 |
| Lagerklasse | 11 - Combustible Solids |
| Gefahrenklasse | Aquatic Chronic 4 |
Anwendungen & Verwendung
Beschreibung
AM251 is a cannabinoid 1 (CB1) receptor 1 antagonist. It binds to CB1 receptors in rat forebrain membrane preparations (Ki = 7.5 nM) and is selective over CB2 receptors in mouse spleen preparations (Ki = 2,290 nM) in radioligand binding assays. AM251 inhibits GTPγS binding induced by the CB receptor agonist CP 55,940 in HEK293 cells expressing human CB1 receptors (EC50 = 8 nM). AM251 (10 mg/kg) decreases immobility time in the forced swim test in wild-type but not CB1 receptor-deficient mice. It reduces fasting-induced food intake and body weight gain in mice when administered at a dose of 30 mg/kg. AM251 also induces GTPγS binding in HEK293 cells expressing the orphan receptor GPR55 (EC50 = 39 nM) and potentiates GABA-induced GABAA receptor currents (EC50 = 0.4 μM). It prevents TGF-β1-induced epithelial-to-mesenchymal transition (EMT), inhibits SMAD2/3 and p38 MAPK activation, and reduces the expression of EMT-related transcription factors in HK-2 renal tubule epithelial cells. AM251 induces cell cycle arrest at the G2/M phase and apoptosis in A375 human melanoma cells.
Verwenden
Inhibitor of CB1 receptors. AM 251is a biarylpyrazole compound which has been considered for many years as the prototypical cannabinoid (CB) receptor antagonist